Faculty of Medicine, Dept. of Histology and Embryology, Hacettepe University, Ankara, Ankara, 06230, Turkey.
Graduate School of Science and Engineering, Department of Bioengineering, Hacettepe University, Ankara, 06230, Turkey.
Stem Cell Res Ther. 2024 Apr 10;15(1):105. doi: 10.1186/s13287-024-03674-8.
Acute hypoxic proximal tubule (PT) injury and subsequent maladaptive repair present high mortality and increased risk of acute kidney injury (AKI) - chronic kidney disease (CKD) transition. Human bone marrow mesenchymal stem cell-derived exosomes (hBMMSC-Exos) as potential cell therapeutics can be translated into clinics if drawbacks on safety and efficacy are clarified. Here, we determined the real-time effective dose and treatment window of allogeneic hBMMSC-Exos, evaluated their performance on the structural and functional integrity of 3D microfluidic acute hypoxic PT injury platform.
hBMMSC-Exos were isolated and characterized. Real-time impedance-based cell proliferation analysis (RTCA) determined the effective dose and treatment window for acute hypoxic PT injury. A 2-lane 3D gravity-driven microfluidic platform was set to mimic PT in vitro. ZO-1, acetylated α-tubulin immunolabelling, and permeability index assessed structural; cell proliferation by WST-1 measured functional integrity of PT.
hBMMSC-Exos induced PT proliferation with ED50 of 172,582 µg/ml at the 26th hour. Hypoxia significantly decreased ZO-1, increased permeability index, and decreased cell proliferation rate on 24-48 h in the microfluidic platform. hBMMSC-Exos reinforced polarity by a 1.72-fold increase in ZO-1, restored permeability by 20/45-fold against 20/155 kDa dextran and increased epithelial proliferation 3-fold compared to control.
The real-time potency assay and 3D gravity-driven microfluidic acute hypoxic PT injury platform precisely demonstrated the therapeutic performance window of allogeneic hBMMSC-Exos on ischemic AKI based on structural and functional cellular data. The novel standardized, non-invasive two-step system validates the cell-based personalized theragnostic tool in a real-time physiological microenvironment prior to safe and efficient clinical usage in nephrology.
急性低氧近端肾小管(PT)损伤及随后的适应性修复会导致高死亡率和增加急性肾损伤(AKI)-慢性肾脏病(CKD)转化的风险。人骨髓间充质干细胞衍生的外泌体(hBMMSC-Exos)作为潜在的细胞治疗药物,如果能明确其安全性和疗效方面的缺陷,就可以转化为临床应用。在这里,我们确定了同种异体 hBMMSC-Exos 的实时有效剂量和治疗窗口,并评估了它们在 3D 微流控急性低氧 PT 损伤平台上对结构和功能完整性的作用。
分离并鉴定 hBMMSC-Exos。实时基于阻抗的细胞增殖分析(RTCA)确定了急性低氧 PT 损伤的有效剂量和治疗窗口。设置了一个 2 道 3D 重力驱动微流控平台来模拟体外的 PT。ZO-1、乙酰化α-微管蛋白免疫标记和通透性指数评估结构;通过 WST-1 测量 PT 的功能完整性来评估细胞增殖。
hBMMSC-Exos 在 26 小时时诱导 PT 增殖的 ED50 为 172582μg/ml。在微流控平台上,缺氧显著降低了 ZO-1 的表达,增加了通透性指数,并在 24-48 小时降低了细胞增殖率。hBMMSC-Exos 通过增加 ZO-1 的表达将极性提高了 1.72 倍,与 20/155 kDa 的葡聚糖相比,恢复了 20/45 倍的通透性,并使上皮细胞增殖增加了 3 倍。
实时效力测定和 3D 重力驱动急性低氧 PT 损伤微流控平台基于结构和功能细胞数据,精确地展示了同种异体 hBMMSC-Exos 在缺血性 AKI 治疗中的治疗作用窗口。新型标准化、非侵入性两步系统在安全、有效地用于肾脏病学之前,在实时生理微环境中验证了基于细胞的个体化治疗诊断工具。